Detection of volume loss using the Nexfin device in blood donors

Autor: Christa Boer, T. A. van Veelen, M. M. W. Koopman, J. Stens, S. B. Nicia

Publikováno v: Anaesthesia, 71(2), 163-170. Wiley-Blackwell
Nicia, S B, van Veelen, T A, Stens, J, Koopman, M M W & Boer, C 2016, ' Detection of volume loss using the Nexfin device in blood donors ', Anaesthesia, vol. 71, no. 2, pp. 163-170 . https://doi.org/10.1111/anae.13283

We investigated which haemodynamic parameters derived from Nexfin non-invasive continuous arterial blood pressure measurements are optimal to detect controlled volume loss in spontaneously breathing subjects. Haemodynamic monitoring was performed in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2f7600feeb77ea413d3730d30803477
https://pubmed.ncbi.nlm.nih.gov/26566706

Short- and long-acting synthetic pentasaccharides

Autor: M. M. W. Koopman, H. R. Büller

Publikováno v: Journal of internal medicine, 254(4), 335-342. Wiley-Blackwell

Inhibition of activated coagulation factor X (FXa) is an attractive target for antithrombotic treatment strategies, because of the central position of FXa in the coagulation cascade. Most of the now available anticoagulant drugs have inhibitory effec

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f406eb90f2a1cee110dc286ab1c3a18d
https://doi.org/10.1046/j.1365-2796.2003.01226.x

Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions

Autor: M M W Koopman, S F T M de Bruijn, Jan Stam, Jan P. Vandenbroucke

Publikováno v: BMJ. 316:589-592

Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis. Design:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::460efa81e0b8905f764b681a80c1eed0
https://doi.org/10.1136/bmj.316.7131.589

An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies

Autor: E P, Mauser-Bunschoten, I, Kleine Budde, S, Lopaciuk, M M W, Koopman, F J M, Van Der Meer, I R O, Novàkovà, P, Ypma, P W G, Van Der Linden, J, Windyga, P F W, Strengers

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 17(3)

Nonafact(®), an ultrapure, monoclonal antibody-purified factor IX concentrate (FIX) was developed to minimize risk of thrombotic complications and viral transmission. To investigate the pharmacokinetics, efficacy and safety, phase III/IV studies wer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a7dbf4e498bf2c5ec29886a281a5097c
https://pubmed.ncbi.nlm.nih.gov/21362109

In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A

Autor: P J M, Vossebeld, M H, Tissing, H M, Van Den Berg, F W G, Leebeek, A, De Goede-Bolder, I R O, NovAkovA, W B J, Gerrits, M, Peters, M M W, Koopman, A, Faber, H, Hiemstra, P, Grob, P F W, Strengers

Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 9(2)

AAFACT, a monoclonal purified, solvent/detergent treated human plasma-derived coagulation factor VIII concentrate obtained from plasma of voluntary, non-remunerated blood donors, is manufactured and marketed in the Netherlands by Sanquin Plasma Produ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::42b21c77ba50a84dc9e14da66b4606c5
https://pubmed.ncbi.nlm.nih.gov/12614366